NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

Tecovirimat showed no efficacy in reducing lesion resolution time or pain in adults with mild to moderate clade II mpox, leading to halted enrollment in the STOMP trial. No safety concerns were noted. The study highlights the importance of clinical trials during outbreaks and continues to assess data for severe cases.

NIH study finds tecovirimat safe but ineffective in reducing mpox lesion resolution time or pain among adults with mild to moderate clade II mpox. Study halted enrollment due to lack of efficacy, with no safety concerns reported.

Tecovirimat, an antiviral drug, showed no significant effect on lesion resolution or pain in adults with mild to moderate clade II mpox, leading to halted enrollment in its clinical trial. No safety issues were reported. The findings highlight the importance of randomized trials in evaluating treatments for infectious diseases like mpox.

Tecovirimat showed no significant effect on lesion resolution or pain in adults with mild to moderate clade II mpox, leading to halted enrollment in its trial. The study underscores the importance of clinical trials in outbreak responses, with ongoing research to address mpox treatment gaps.

The STOMP study found tecovirimat ineffective in reducing lesion resolution time or pain for mild to moderate clade II mpox patients, leading to halted enrollment. No safety issues were noted. The study emphasizes the need for randomized trials during outbreaks and continues to explore mpox treatments.

The global AI in Clinical Trials market is projected to grow from USD 1.42 billion in 2023 to USD 8.5 billion by 2035, at a CAGR of 16%. AI integration aims to streamline clinical trials by optimizing trial design, patient recruitment, and data analysis, addressing challenges like high costs and trial failures. Key drivers include venture capital funding and partnerships, with oncological disorders leading in AI application. The market is segmented by trial phase, therapeutic area, and geography, with Asia-Pacific currently dominating.

The global HIV clinical trials market is projected to grow from USD 1.30 billion in 2024 to USD 2.42 billion by 2034, at a CAGR of 6.4%. Key factors driving growth include increasing HIV infections, R&D investments, drug approvals, and HIV vaccine trials. Phase I trials held the largest revenue share in 2024, while the Asia Pacific region is expected to register the fastest growth. Major companies like Gilead Sciences and Janssen Global Services are significant contributors to the market.

Soligenix announces continued improvement in HyBryte™-treated patients and lesions post-treatment, with statistically significant efficacy against plaque lesions compared to Valchlor®, and no safety concerns raised.